Investigational New Antiretrovirals: What’s Hot! (On-Demand Webinar)
On-Demand Webinar: Investigational New Antiretrovirals: What’s Hot!
Presenter: Joseph J. Eron, Jr, MD
Release date: April 6, 2021
Expiration date: April 6, 2022
CME Credit Available: 1.25 AMA PRA Category 1 Credits™
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing education effort for physicians on the evolving challenges of managing HIV disease. This webinar will discuss antiretroviral agents that are in clinical development or late stage preclinical development and very likely to enter human trials. Additionally, this webinar will review mechanisms of action, antiretroviral activity, and information on adverse events and side effect. Lastly, it will discuss where these drugs may fit into treatment strategies for people with HIV for those agents in the later stage of clinical development.
On completion of this webinar, learners will be able to:
- Describe why new antiretroviral are still needed for the treatment and prevention of HIV-1
- List at least 2 new antiretroviral agents that work by new mechanisms and are different from currently approved agents
- Summarize possible ways that long-acting antiretroviral agents will be administered in the future
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, pharmacists, and other health professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 03/22/21)
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 04/6/21)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 04/6/21)
All relevant financial relationships have been mitigated.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co., Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.
How to Claim Credit
- Start the Activity by clicking "START COURSE" located above.
Please note that the "START COURSE" will no longer be visible once you clicked it once.
- Watch the webinar here.
- Return to this page and follow this link to the evaluation form.
- Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
- Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.